Imaging and response criteria in gliomas

Current Opinion in Oncology

Volumn 22, Issue 6, 2010, Pages 598-603

  Gerstner, Elizabeth R ^a   Batchelor, Tracy T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

gliomas; MRI; PET; response criteria

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; FERUMOXYTOL; FLUORODEOXYGLUCOSE; GADOLINIUM; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN INHIBITOR;

ACCURACY; ANTIANGIOGENIC THERAPY; BLOOD BRAIN BARRIER; BLOOD VESSEL DIAMETER; BLOOD VESSEL PERMEABILITY; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CANCER GROWTH; CANCER SURGERY; CELL DENSITY; CELL PROLIFERATION; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; CYST; DIFFUSION COEFFICIENT; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; DYNAMIC SUSCEPTIBILITY CONTRAST MAGNETIC RESONANCE IMAGING; FRACTIONAL ANISOTROPY; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOXIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROMOTER REGION; RECURRENT CANCER; REVIEW; SCINTIGRAPHY; STANDARDIZATION; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN NEOPLASMS; GLIOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED;

EID: 77958479632     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833de96e     Document Type: Review

References (39)

1. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncologyworking group. J Clin Oncol 2010; 28:1963-1972.
2. Macdonald DR, Cascino TL, Schold SC, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280.
3. Vos MJ, Uitdehaag BM, Barkhof F, et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 2003; 60:826-830.
4. Ulmer S, BragaTA, Barker FG 2nd, et al. Clinical and radiographic features of peritumoral infarction following resection of glioblastoma. Neurology 2006; 67:1668-1670.
5. Henson JW, Ulmer S, Harris GJ. Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008; 29:419-424.
6. Gerstner ER, McNamara MB, Norden AD, et al. Effect of adding temozolo-mide to radiation therapy on the incidence of pseudo-progression. J Neu-rooncol 2009; 94:97-101.
7. Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9:453-461.
8. De Wit MC, De Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004; 63:535-537.
9. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26:2192-2197.
10. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
11. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGFreceptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95.
12. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25:4722-4729.
13. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-4740.
14. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, avascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survivaldespite persistent brain tumor growth in mice. J Clin Oncol 2009; 27:2542-2552.
15. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306-314.
16. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61:6624-6628.
17. Galanis E, Buckner JC, Maurer MJ, et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro-oncol 2006; 8:156-165.
18. Shah GD, Kesari S, Xu R, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-oncol 2006; 8:38-46.
19. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009; 30:552-558.
20. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation ofpseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytolvs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2010. [Epub aheadof print]
21. Tsien C, Galban CJ, Chenevert TL, et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression inhigh-grade glioma. J Clin Oncol 2010; 28:2293-2299.
22. Quarles CC, Schmainda KM. Assessment of the morphological and functionaleffects of the antiangiogenic agent SU11657 on 9L gliosarcoma vasculatureusing dynamic susceptibility contrast MRI. Magn Reson Med 2007; 57:680-687.
23. Sorensen AG, BatchelorTT, Zhang WT, et al. A 'vascular normalization index' as potential mechanistic biomarker to predict survival after a single dose ofcediranib in recurrent glioblastoma patients. Cancer Res 2009; 69:5296-5300.
24. Claes A, Wesseling P, Jeuken J, et al. Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008; 7:71-78.
25. Tochon-Danguy H, Sachinidis JI, Chan F, et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002; 29:191-197.
26. Valk P, Mathis CA, Prados MD, et al. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 1992; 33:2133-2137.
27. Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009; 69:4502-4509.
28. 18F-fluoro-misonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006; 47:410-418.
29. 18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008; 14:2623-2630.
30. Chenevert T, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92:2029-2036.
31. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006; 241:839-846.
32. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 2003; 21:1094-1100.
33. Moffat B, Chenevert TL, Lawrence TS, et al. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci \USA 2005; 102:5524-5529.
34. 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 2004; 10:916-928.
35. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010; 28:e91-e93.
36. Ullrich R, Backes H, Li H, et al. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008; 14:2049-2055.
37. 18F-FDG. J Nucl Med 2005; 46:945-952.
38. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007; 25:4714-4721.
39. 18F- fluorothymidine in a genetically engineered mouse model of high-grade gliomas. J Nucl Med 2008; 49:422-429.